Genmab Amends Ofatumumab Pivotal Study In NHL To Single Arm Study
Genmab A/S (OMX: GEN) announced it has amended the design of an ongoing pivotal study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non Hodgkin’s lymphoma (NHL) to a single arm trial that will now include approximately 81 patients. All patients will receive one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab.
